QQ客服 官方微博 反馈留言

	Regulation on SIRT1-PGC-1 alpha/Nrf2 pathway together with selective inhibition of aldose reductase makes compound hr5F a potential agent for the treatment of diabetic complications
	Wang, Zhihua[1]; Yuan, Sheng[1,2]; Li, Yanbing[1,2]; Zhang, Zhe[1]; Xiao, Wei[1]; Tang, Dan[1]; Ye, Kaihe[1]; Liu, Zhijun[1]; Wang, Congcong[3]; Zheng, Yixiong[3]
	2018
卷号	150页码:54
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4445215
专题	暨南大学
作者单位	1.[1]Jinan Univ, Coll Pharm, Guangzhou 510632, Guangdong, Peoples R China 2.[2]Jinan Univ, Guangdong Prov Key Lab Pharmacodynam Constituents, Guangzhou 510632, Guangdong, Peoples R China 3.[3]Zhongkai Univ Agr & Engn, Coll Agr, Guangzhou 510225, Guangdong, Peoples R China
推荐引用方式 GB/T 7714	Wang, Zhihua[1],Yuan, Sheng[1,2],Li, Yanbing[1,2],et al. Regulation on SIRT1-PGC-1 alpha/Nrf2 pathway together with selective inhibition of aldose reductase makes compound hr5F a potential agent for the treatment of diabetic complications[J],2018,150:54.
APA	Wang, Zhihua[1].,Yuan, Sheng[1,2].,Li, Yanbing[1,2].,Zhang, Zhe[1].,Xiao, Wei[1].,...&Chen, Heru[1,2].(2018).Regulation on SIRT1-PGC-1 alpha/Nrf2 pathway together with selective inhibition of aldose reductase makes compound hr5F a potential agent for the treatment of diabetic complications.,150,54.
MLA	Wang, Zhihua[1],et al."Regulation on SIRT1-PGC-1 alpha/Nrf2 pathway together with selective inhibition of aldose reductase makes compound hr5F a potential agent for the treatment of diabetic complications".150(2018):54.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。